Literature DB >> 6184663

Substance P reduces tail-flick latency: implications for chronic pain syndromes.

Kiran Yasphal1, D M Wright, J L Henry.   

Abstract

In the awake restrained rat the intrathecal administration of substance P or the partial substance P homologue eledoisin-related peptide (ERP) reduced reaction time to a noxious radiant heat stimulus and, at high doses, produced additional behavioural responses suggesting that the animals had reacted to what they perceived as a painful stimulus. The reduction in tail-flick latency was observed as early as 30 sec following peptide administration peaked at 1 min and persisted for 5-10 min, after which an overshoot of the response (i.e., an increase in reaction time) was observed. The responses varied in their magnitude with the amount of peptide given, substance P being approximately 4 times more potent on a molar basis than ERP. Intrathecal administration of an equal volume of vehicle (artificial cerebrospinal fluid) had no effect on tail-flick latency and failed to produce any of the other behavioural changes. The following interpretations are made. The decrease in tail-flick latency suggests that pain threshold was decreased, and the dramatic behavioural effects seen at high doses suggest that an excess of substance P in the spinal cord is capable of producing a painful sensation. The rapid onset of the response suggests rapid penetration of substance P and ERP to the appropriate receptors, and the rapid decay of the response suggests rapid removal. Taken together, these results are consistent with the earlier suggestion that substance P plays a role as an excitatory agent in sensory pathways subserving pain. It is proposed that some conditions of chronic pain in man may therefore be due to an overabundant amount of substance P. This is complementary to a second proposal that other cases of chronic pain may be due to a supersensitivity of substance P receptors. The former is more likely to be associated with organic disorders, the latter with nerve damage, e.g. with causalgia, the neuralgias and perhaps some cases of phantom limb pain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184663     DOI: 10.1016/0304-3959(82)90096-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  11 in total

1.  Substance P markedly potentiates the antinociceptive effects of morphine sulfate administered at the spinal level.

Authors:  R M Kream; T Kato; H Shimonaka; J E Marchand; W H Wurm
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

2.  In vitro prostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin.

Authors:  D M Dirig; T L Yaksh
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  Evidence for tonic activation of NK-1 receptors during the second phase of the formalin test in the Rat.

Authors:  J L Henry; K Yashpal; G M Pitcher; J Chabot; T J Coderre
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

4.  The effects of substance P analogues on the scratching, biting and licking response induced by intrathecal injection of N-methyl-D-aspartate in mice.

Authors:  T Sakurada; Y Manome; K Tan-No; S Sakurada; K Kisara
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

5.  Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580.

Authors:  N M Rupniak; S Boyce; A R Williams; G Cook; J Longmore; G R Seabrook; M Caeser; S D Iversen; R G Hill
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  Desensitization to substance P following intrathecal injection. A technique for investigating the role of substance P in nociception.

Authors:  J Sawynok; G Robertson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

7.  Behavioural effects of intrathecally injected tachykinins in rats with peripheral nerve transection.

Authors:  H Kuwahara; T Sakurada; S Sakurada; A Yonezawa; R Ando; K Kisara; F Osakada; E Munekata
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

8.  Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization.

Authors:  S M Moochhala; J Sawynok
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

9.  Cerebrolysin improves sciatic nerve dysfunction in a mouse model of diabetic peripheral neuropathy.

Authors:  Han-Yu Dong; Xin-Mei Jiang; Chun-Bo Niu; Lin Du; Jun-Yan Feng; Fei-Yong Jia
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

10.  Differences in electrophysiological properties of functionally identified nociceptive sensory neurons in an animal model of cancer-induced bone pain.

Authors:  Yong Fang Zhu; Robert Ungard; Eric Seidlitz; Natalie Zacal; Jan Huizinga; James L Henry; Gurmit Singh
Journal:  Mol Pain       Date:  2016-03-01       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.